D. Cantero

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors

L. Lebrun, I. Salmon, B. Meléndez, 2020, Neuro-oncology advances.

Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing

Juan F. García, J. Borrás, I. Salmon, 2018, Journal of neuropathology and experimental neurology.

Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma

A. Hernández-Laín, D. Cantero, J. Sepúlveda, 2016, Neurology.

Milder forms of α-sarcoglicanopathies diagnosed in adulthood by NGS analysis

E. Gallardo, A. Hernández-Laín, D. Cantero, 2018, Journal of the Neurological Sciences.

Autosomal dominant distal myopathy with nemaline rods due to p.Glu197Asp mutation in ACTA1

A. Hernández-Laín, D. Cantero, Ó. Toldos, 2019, Neuromuscular Disorders.

Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype

B. Herránz, T. Cejalvo, A. Hernández-Laín, 2020, Cancers.

Immune profiling of gliomas reveals a connection with Tau function and the tumor vasculature

B. Herránz, T. Cejalvo, A. Hernández-Laín, 2020, bioRxiv.

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma

M. Pajares, A. Hernández-Laín, P. Sánchez-Gómez, 2015, Molecular Cancer Therapeutics.

Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab

G. De Velasco, A. Hernández-Laín, P. Sánchez-Gómez, 2019, Clinical and Translational Oncology.